Arbutus Biopharma Corporation ABUS Business Segments — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's business segments — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's business segments — revenue?
- Arbutus Biopharma Corporation (ABUS) reported business segments — revenue of $179.13M in Q1 2026.
- How has Arbutus Biopharma Corporation's business segments — revenue changed year-over-year?
- Arbutus Biopharma Corporation's business segments — revenue increased by 10054.5% year-over-year, from $1.76M to $179.13M.
- What is the long-term trend for Arbutus Biopharma Corporation's business segments — revenue?
- Over 2 years (2023 to 2025), Arbutus Biopharma Corporation's business segments — revenue has grown at a -11.9% compound annual growth rate (CAGR), from $18.14M to $14.08M.
- What does business segments — revenue mean?
- This represents the total gross income generated by the company's primary business segment through its core operations, including product sales, licensing agreements, and service contracts. It serves as a key indicator of the segment's market traction and ability to monetize its intellectual property or therapeutic assets.